![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 09, 2017 9:24:39 AM
Someone posted an article of how big pharma gets the lions share of deals with small regenerative pharma, because of the costs associated with phase 3 trials. This is why we have seen no deal with any big pharma. Pluristem wants a deal that will give them their rightful share of the pie.
If they do have something that they know will raise the price up to the $3 to $5 range, they will sell a chunk of those shares, giving them a substantial chunk of change which would then provide funding for all that they need. Being fully funded is the only way they will be able to make a deal that would be beneficial to Pluristem. It would also increase our institutional ownership substantially, as I would imagine that's where the bulk would go.
If they were thinking of a big dilution at these prices, they know the prices would tank, and they would be in the same boat within a few quarters. If they were going to do it, it would have been done like the last one.
That big bonus they got, HAS to be for something, it just has to. Most likely something with ARS but who knows. As long as it's something. That's the scenario I am seeing play out, or one I'm hoping for anyways. Just hope it comes to fruition before September 15th.
Glta
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM